History of lower-limb complications and risk of cancer death in people with type 2 diabetes

Table 4 Risk of cancer death according to history of lower-limb complications at baseline

		Cancer death, n (%)		Model 1		Model 2
		No, n	Yes, n (%)	Hazard ratio (95% CI)	p	Hazard ratio (95% CI)	p
Lower-limb complication	No	6702	145 (2.1)	1.62 (1.29–2.04)	< 0.0001	1.53 (1.21–1.94)	0.0004
Lower-limb complication	Yes	4122	171 (4.0)	1.62 (1.29–2.04)	< 0.0001	1.53 (1.21–1.94)	0.0004
Peripheral arterial disease	No	8488	213 (2.4)	1.43 (1.12–1.83)	0.004	1.32 (1.02–1.70)	0.03
Peripheral arterial disease	Yes	2336	103 (4.2)	1.43 (1.12–1.83)	0.004	1.32 (1.02–1.70)	0.03
Peripheral neuropathy	No	7971	196 (2.4)	1.49 (1.19–1.88)	0.0006	1.41 (1.11–1.79)	0.004
Peripheral neuropathy	Yes	2853	120 (4.0)	1.49 (1.19–1.88)	0.0006	1.41 (1.11–1.79)	0.004

Model 1: age (and its square), sex, region of origin, and study allocations
Model 2: model 1 plus duration of diabetes, body mass index (and its square), waist circumference (and its square), systolic and diastolic blood pressure (and their squares), HbA1c (and its square), urinary ACR, eGFR (and its square), total cholesterol, HDL cholesterol, triglycerides, MMSE score, education accomplishment, history of ever or current smoking, history of past or current alcohol drinking, history of CAD, cerebrovascular disease, diabetic retinopathy or dementia, and use of metformin, insulin, antihypertensive, statin or antiplatelet therapy

ISSN: 1475-2840